Similarly, models carrying optineurin C-terminal truncation (Optn470T) or point mutation (OptnD477N), mimicking some ALS patient mutations that disrupt ubiquitin binding, showed no overt neuroinflammation or ALS pathology (at two months, and one year, respectively)18,24. Here, OPTN is linked to amyotrophic lateral sclerosis.